SanBio (4592 JP): Better-Than-Expected Operating Loss in FY23; Product Approval Expected in FY24
In FY23, SanBio reported operating loss of ¥7.9B, better than guidance of ¥8.1B. Operating loss is expected to narrowed to ¥4.6B in FY24. The...
616 Views
SanBio (4592 JP): Remains Unlucky for Second-Time; Delay in First Product Approval Weighs Heavily
SanBio has deferred the approval timeline of its first product SB623 in Japan for the second time this year. The company expects SB623 approval is...
352 Views
SanBio (4592 JP): Marketing Approval of First Product Expected This Year in Japan
With promising clinical trial data and priority review status, SanBio’s lead drug candidate SB623 is expected to be approved in Japan this year....
796 Views
Ocumension Therapeutics IPO Initiation: Look into My Eyes
Ocumension Therapeutics (1764324D CH) is a China-based ophthalmic pharmaceutical company dedicated to identifying, developing and commercializing...
596 Views
Japan - Shorts Cover as Market Rallies
The short notional in the market for the week ended 25 October is US$26.82bn (down by US$0.91bn) with the largest short positions in Itochu Corp...
626 Views